NCT03801668View on ClinicalTrials.gov

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

PHASE3UnknownINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

March 8, 2019

Primary Completion Date

December 31, 2022

Study Completion Date

March 31, 2023

Conditions
Gastric Cancer
Interventions
DRUG

Albumin-bound Paclitaxel plus S-1

Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.

DRUG

Oxaliplatin plus S-1

Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.

Trial Locations (1)

430030

RECRUITING

Tongji hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Sponsors
All Listed Sponsors
collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

lead

Huazhong University of Science and Technology

OTHER

NCT03801668 - Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma | Biotech Hunter | Biotech Hunter